ocular photodynamic therapy

ocular photodynamic therapy

Ophthalmology A process for managing age-related macular degeneration in which vertoporfin is administered, concentrates in the eye, and the macula is zapped with a laser. See Age-related macular degeneration.
Mentioned in ?
References in periodicals archive ?
NASDAQ: QLTI; TSX: QLT) and Novartis Ophthalmics, the eye health unit of Novartis AG announced today that on April 1, 2004 the Centers for Medicare and Medicaid Services (CMS) will implement its decision to provide coverage for ocular photodynamic therapy (OPT) with Visudyne(R) (verteporfin) to patients with age- related macular degeneration (AMD) who have occult and minimally classic lesions that are four disc areas or less in size and show evidence of recent disease progression.
Ocular Photodynamic Therapy (OPT) - Verteporfin Therapy for Age-related Macular Degeneration (AMD) (updated 4-04)
Medicare already offers coverage for Ocular Photodynamic Therapy (OPT) in AMD with predominantly classic lesions.
Today, the American Association of People with Disabilities (AAPD), the American Council of the Blind (ACB) and the Gray Panthers commended the Centers for Medicare and Medicaid Services (CMS) for providing Medicare coverage of ocular photodynamic therapy (OPT) with verteporfin for the treatment of occult age-related macular degeneration (AMD).
These leading disability and senior organizations are joining together to protect the rights of Medicare beneficiaries and challenge the Centers for Medicare and Medicaid Services' (CMS) erroneous decision to deny Medicare coverage of ocular photodynamic therapy (OPT) with verteporfin ("Visudyne") for the treatment of age-related macular degeneration (AMD) with occult lesions.
The treatment, called Ocular Photodynamic Therapy (OPT) with Verteporfin ("Visudyne") can significantly slow the destruction of vision, which results when blood vessels leak into the space just beneath a patient's retina.
Based on these results, ocular photodynamic therapy with Visudyne should be considered as a treatment for AMD patients with lesions composed of occult without classic CNV with presumed recent disease progression," said Dr.